Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Celgene Corporation
Roche Pharma AG
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:
NCT01718379
First received: October 23, 2012
Last updated: March 19, 2014
Last verified: October 2012

October 23, 2012
March 19, 2014
July 2010
June 2015   (final data collection date for primary outcome measure)
Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant [ Time Frame: After 4 months of treatment ] [ Designated as safety issue: Yes ]

Primary outcome is a complete or partial response defined by the IWG 2006 criteria observed after 4 months of treatment. Comparison in the rate of response between the two groups will be performed with Chi-square test or if necessary Fisher exact test.

Same analyzes will be performed with the IWG 2000 response definition .

Same as current
Complete list of historical versions of study NCT01718379 on ClinicalTrials.gov Archive Site
will be to assess the safety of Lenalidomide and of its combination with Epoetin beta [ Time Frame: After 2 months of treatment ] [ Designated as safety issue: Yes ]
  • Safety of Lenalidomide and of its combination with Epoetin beta: adverse events (type, frequency, severity) and relationship of adverse events to study drug
  • % of major HI-E and minor HI-E after 4 courses according to IWG 2000 criteria
  • Erythroid response duration
  • Time to response
  • Time to progression according to IPSS
  • RBC transfusion independence
  • Prognostic factors of response
  • Survival
  • Quality of life
Same as current
Not Provided
Not Provided
 
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.

The goal of the present study is to assess, through a randomized phase II trial, the efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent, ESA-resistant, IPSS low and intermediate-1 risk MDS patients without chromosome 5 abnormality.

Patients will receive either Lenalidomide alone or Lenalidomide and Epoetin beta for 4 months. Responders will be eligible for maintenance treatment with cycles identical to the first cycles, until relapse occurs or until unacceptable toxicity.

This is a multi-center, open-label, randomized, Phase II study.

Patients will be treated either with arm A or B

  • Arm A: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.
  • Arm B: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).

Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.

The patients will be followed every 3 months for 12 months

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Myelodysplastic Syndromes
  • Drug: Lenalidomide
    Lenalidomide:10 mg per day during 21 days
    Other Name: Revlimid
  • Drug: Epoetin beta
    Epoetin beta: 60,000 Units/week.
    Other Name: NEORECORMON
  • Experimental: Arm A

    Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.

    Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

    Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.

    The patients will be followed every 3 months for 12 months

    Intervention: Drug: Lenalidomide
  • Experimental: Arm B

    Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).

    Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

    Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.

    The patients will be followed every 3 months for 12 months

    Intervention: Drug: Epoetin beta
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
132
January 2016
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

MDS defined as

  • Low or int-1 IPSS score
  • Documented absence of chromosome 5 abnormality (del(5q) or -5 karyotype)
  • De novo MDS, excluding therapy-related MDS AND
  • Transfusion dependance (requirement of at least 4 units of RBC transfusions every 8 weeks )
  • Resistance or loss of response to a previous treatment with Epoetin alpha/beta (at least 60,000 Units/w) or Darbepoetin (at least 250 µg/w), for at least 12 weeks
  • Ineligibility for allogeneic stem cell transplantation or intensive chemotherapy during the next 12 months
  • ECOG performance status ≤ 2
  • Age ≥ 18 years
  • Life expectancy ≥ 3 months
  • Adequate liver function (transaminases serum levels ≤ 3N)
  • Adequate renal function (calculate creatinine clearance > 50 ml/min)
  • Female subjects of chilbearing potential* must :

Agree to use effective contraception without interruption throughout the study and for at least 4 weeks after the end of treatment

• Men must: Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and during one week after end of treatment if their partner is of childbearing potential.

Exclusion Criteria:

  • Active serious infection not controlled by oral or intravenous antibiotics
  • Platelets less than 50 G/L
  • Prior history of deep vein thrombosis or pulmonary embolism
  • Previous treatment by Thalidomide
  • Treatment with any investigational antileukemic agent or chemotherapy at least 6 weeks prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy were given
  • Rapidely progressive disease with copromised organ function judged to be life-threatening by the Investigator
  • Pregnant or lactating female
  • Known human immunodeficiency virus (HIV) infection
  • Known active hepatitis B and/or C virus infection
  • Hypersensitivity or intolerance to Lenalidomide or any of the excipients
  • Hypersensitivity to Epoetin beta or any of the excipients
  • Uncontrolled arterial hypertension
  • Any history of malignancy (other than myelodysplastic syndrome) unless the patient has remained disease free for more than 5 years
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France,   Monaco
 
NCT01718379
GFM-Len-Epo-08
Yes
Groupe Francophone des Myelodysplasies
Groupe Francophone des Myelodysplasies
  • Celgene Corporation
  • Roche Pharma AG
Principal Investigator: Andréa TOMA, MD Groupe Francophone des Myelodysplasies
Study Director: François Dreyfus, MD Groupe Francophone des Myelodysplasies
Groupe Francophone des Myelodysplasies
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP